Genetic medicines company harnessing Protein Splicing to develop the next-gen of gene therapies. Based on technology developed in the Muir Lab at @Princeton.
Barcelona
- Tweets 215
- Following 55
- Followers 325
- Likes 151
Next week, join our team at #ESGCT2026. We'll be presenting a poster highlighting SpliceBio’s protein splicing platform in the central nervous system (CNS), including translational validation in non-human primates. We look forward to connecting!
1
47
Our Clinical Project Manager Lauren Hauser (pictured in pink) recently represented SpliceBio at an event hosted by the @CarrollCenter. We value opportunities to connect with organizations like the Carroll Center that share our commitment to supporting the vision loss community.
3
61
This #WorldSightDay, we’re raising awareness of Stargardt disease and the impact progressive central vision loss can have on everyday activities like reading a book. At SpliceBio, we’re advancing SB-007, our investigational gene therapy for #Stargardt disease.
1
2
81
Join our CBO Gerard Caelles at #Sachs_BEF in Basel this week. He will present our work in #CNS and join the Neuroscience Innovation Panel with other industry leaders.
1
61
Our CEO Miquel Vila-Perello is heading to Phoenix for @alliancerm 2026 Cell & Gene Meeting on the Mesa.
We look forward to connecting with colleagues across the cell and gene therapy community on Monday and throughout the week. We’ll meet you at #CGMesa26!
1
58
We’re honored to be nominated for the 2026 Prix Galien Patient First Award in Honor of Michael J. Fox. This recognition reflects our work alongside the #StargardtDisease community to deepen our understanding of the disease and advance new treatment options. Thank you @GalienFdn.
1
2
74
At #ISER2026, our Head of Ophthalmology, Julián Esteve will present on how our protein splicing platform is overcoming AAV cargo limits to unlock delivery of large genes. He'll also share how the technology is being applied in SB-007, our lead program for #Stargardt disease.
1
280
Ens fa molta il·lusió haver donat suport al #BBQ2026 a patrocinadors Silver: la gran trobada d’estiu de la comunitat biotecnològica, healthtech i de ciències de la vida de Catalunya. Gràcies a @CataloniaHealth per una altra fantàstica edició. Ens veiem l'any vinent!
1
66
Today is Rare Chromosome and Gene Disorder Awareness Day - a time to recognize the individuals and families affected by rare genetic conditions, including inherited retinal diseases such as #Stargardt disease. We honor their resilience and the importance of continued innovation.
1
1
78
Our CEO Miquel Vila-Perello joined RARECast by @GlobalGenes to talk about why many rare diseases have long been out of reach for gene therapy and how SpliceBio is working to change that.
1
1
60
This Monday, we're in Leicester for @UKEyeGenetics
Group (UK-EGG) 2026! Our CMO will present on conducting clinical trials, navigating the regulatory process and the importance of communication - fundamental elements to our mission of advancing #geneticmedicines.
1
45
Last week, our team came together for a retreat filled with reflection, connection, and plenty of laughs! Experiences like these reinforce something we believe deeply: investing in our people is essential to building a strong culture and advancing our mission.
1
476
#Stargardt disease is caused by mutations in ABCA4 - a gene too large for traditional gene therapy. We're advancing protein splicing to enable large-gene delivery and address the root cause of a disease with no approved treatments.
1
205
Great time at #ARVO2026 & #ASGCT2026! We were proud to share progress on our clinical program SB-007 for #Stargardt disease and engage in conversations with the broader #genetherapy community. Thank you to everyone who connected. We’re energized by the momentum!
2
173
#Stargardt disease has no approved treatments. This #HealthyVisionMonth, we’re raising awareness of inherited retinal diseases. At SpliceBio, we’re working to advance genetic medicines using protein splicing to address diseases caused by mutations in large genes.
123
We’re heading to #ASGCT2026 next week! Looking forward to connecting with the community, sharing insights, and contributing to the conversation around #genetherapy at the @ASGCTherapy Annual Meeting. See you there!
1
89
Great science starts with great people. Today, we celebrate the SpliceBio team whose passion and collaboration power our work in genetic medicines. Thank you for all you do. Happy #InternationalWorkersDay!
65
Feliç #SantJordi i #WorldBookDay 🌹📖Avui celebrem una tradició catalana de llibres, roses i històries amb el nostre equip a Barcelona. Un dia per celebrar l’amor i la cultura, amb roses per a tothom!
1
1
70
Our CMO Aniz Girach will present at the Annual Retinal Therapeutics Innovation Summit in Denver, co-hosted by @FightBlindness and @CaseyEye. He’ll share the progress of our clinical program SB-007, a third-generation intein-based dual AAV in development for Stargardt disease.
1
1
134
Our work in genetic medicines is guided by shared values and scientific excellence. We’re grateful to the women at SpliceBio and to those everywhere whose work helps translate discovery into transformative therapies for patients.
69
We’re ready for an active week ahead engaging with the #biotech community! Logistics below. We look forward to sharing our progress and connecting with partners.
75
For #RareDiseaseDay, we came together to name our newest plush teammate, “Tira,” inspired by a zebra in Kenya born with a rare genetic condition that altered her stripe pattern.🦓Tira is a reminder of why we do this work and who we do it for.
1
60
We have a fierce appreciation for women in STEM! On International Day of Women and Girls in Science, we recognize all of the incredible women at SpliceBio who are transforming the future of genetic medicines and are paving the way for future generations. #WomeninSTEM
3
3
137
#Stargardt disease is a condition that leads to central vision loss & blindness. Caused by biallelic mutations in the ABCA4 gene, it remains a significant unmet need with no approved treatments. This #LowVisionAwarenessMonth, learn how SB-007 targets the underlying genetic cause.
1
1
4
160
We are pleased to announce that the first patient has been dosed in the Part B dose expansion portion of our Phase 1/2 ASTRA clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for the treatment of #Stargardt disease.
2
3
4
895
We're thrilled to welcome Don Munoz to SpliceBio as our CFO. With deep financial expertise and broad experience within the life sciences industry, Don will be instrumental as we enter our next stages of development and position SpliceBio for long-term value creation.
1
3
113
San Francisco, here we come! Next week, the
SpliceBio team will join industry colleagues at the
J.P. Morgan Healthcare Conference. We’re
looking forward to meaningful conversations and
new connections at #JPM26.
1
2
3
396
We’re proud of the milestones and culture we
built together in 2025. From musical bingo to
closing our Series B financing, plus an ugly
sweater contest & kudos shared across the team,
it was a year of connection & progress. Wishing
everyone a joyful holiday season from SpliceBio.
1
1
1,363
Thrilled to win 'Series B Raise of the Year' at #LifestarAwards 2025! This award recognizes our record-breaking $135M Series B, the largest biotech raise in Spain to date. Grateful to our investors & team for their commitment to advancing the next wave of #geneticmedicines.
1
3
143
CEO Miquel Vila-Perello, CBO Gerard Caelles and CMO Aniz Girach look forward to connecting in London to discuss our #genetherapy approach for #stargardtdisease as well as our pipeline in ophthalmology and neurology. See you at #Jefferies2025!
1
3
364
Our co-founder and CEO traveled to Vienna this week to participate in a dynamic panel of strategic advisors discussing our pivotal $135M Series B financing. Great conversation, amazing energy and a big thank you to everyone at #BioEurope2025!
1
72
CEO, Miquel Vila-Perello, will join a panel of strategic investors who played a key role in our pivotal $135M Series B financing at #BIOEurope in 📍Vienna, Austria. Learn more: informaconnect.com/bioeurope…
2
103
We're a finalist for the 2025 European #LifestarAwards in two categories: ‘Biotech of the Year’ & ‘Best Series B Raise!’ This honor underscores our mission to develop the next-gen of #genetherapies & inspires us to keep pushing the boundaries of what’s possible for patients.
47
#StargardtDisease blurs central vision and can ultimately cause blindness. With no approved treatments available, we’re addressing this unmet need with our lead program SB-007, the first dual AAV gene therapy in clinical development. #BlindnessAwarenessMonth
1
2
124
#ICYMI: SpliceBio’s VP of Clinical Operations, John Tobin and Sr. Director of Clinical Development, Feride Sahin, joined The @CarrollCenter for the Blind for a live discussion on our gene therapy approach in #stargardtdisease. Watch here ➡️ youtube.com/watch?v=7-qXo8FJ…
1
1
166
As #ESGCT2025 wraps up, our team is feeling energized and inspired! Connecting with colleagues and partners reinforces why our mission to develop the next generation of #genetherapies is so important.
3
153
SpliceBio CEO looks forward to speaking on The Company View panel during #CGMesa25's pre-conference ARM CEO and Investor Summit. We look forward to connecting with industry professionals and peers in Phoenix on Sunday and throughout the week!
77
We’re thrilled to be shortlisted for the 2025 #ScripAwards in the Business Development Team of the Year category! Congratulations to the SpliceBio Team and all of the finalists. We are looking forward to celebrating in December! Learn more ➡️ citeline.com/en/awards/scrip…
1
67
We are excited to join @CarrollCenter's upcoming webinar, “Pioneering a Novel Gene Therapy for #StargardtDisease,” on 📅October 2nd at 12pm ET! Learn more and register here: carroll.org/events/splicebio…
1
69
From academic research to leading a global biotech company focused on innovative #genetherapy treatments, hear from SpliceBio’s co-founder and CEO, Miquel Vila-Perello, on the #ClinicalTrialblazers podcast. Tune in here ➡️ youtube.com/watch?v=NJFbu5Ym…
114
We're proud to sponsor the International Society for Genetic Eye Diseases and Retinoblastoma (ISGEDR) Congress in Oslo, Sept 11-13! Learn more ➡️ isgedr.com/
1
46
Are you heading to #ATE2025 in📍Barcelona, Sept 2–4? Our CEO & CBO will be speaking across multiple sessions from building an investor-ready biotech to funding strategies and emerging #genetherapy technology. Learn more: phacilitate.com/advanced-the…
1
2
3
181
Don’t miss @CataloniaHealth’s BBQ 2025! ☀️#SpliceBio is proud to be a sponsor of this key biotech event.
Join 400+ health innovators for an evening of networking & celebration!
📅 July 10
📍 Barcelona
#Biotech #LifeSciences
2
119
📽️ Tune in to @CGT_Insights's webinar to hear from our VP of Regulatory Affairs & Quality, Leigh Shaw!
A panel of experts will explore the evolving CGT regulatory landscape with a focus on patient safety.
📅 1 July | 🕓16:00 BST / 17:00 CEST
🔗 Register: bit.ly/3I9Aw1O
1
113
#Stargardtdisease patients currently have no approved treatments for this inherited retinal disorder. Our lead gene therapy, SB-007, is designed to address the underlying genetic cause of the disease with the potential to treat all patients. Discover more: bit.ly/3ZpxYmi
2
189
SpliceBio takes over Times Square! 🗽
Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower.
Huge thanks to our team & investors powering the next wave of genetic medicines! 💡
1
1
8
1,453
Yesterday, we announced the close of a $135M Series B financing to support clinical development of SB-007 for #StargardtDisease, including the ongoing Phase 1/2 ASTRA and POLARIS studies. Stay tuned as we advance our broader pipeline of genetic medicines. bit.ly/3ZpxYmi
3
5
1,224
We’re proud to close a $135M Series B! Huge thanks to our amazing team & investors whose passion drives next-generation gene therapies.
Our Co-Founder & CEO, Miquel Vila-Perelló, shares his thoughts on this milestone and what’s next — read more here: bit.ly/3ZpxYmi
2
11
2,914
🌟Financing milestone! #SpliceBio closes $135M Series B to:
🚀Advance SB-007 for #StargardtDisease
🔬Expand our genetic medicine pipeline
Read more: bit.ly/3ZpxYmi
6
15
20,246
We’re proud to join the Community Zoom session hosted by @StargardtsC to share clinical progress on our lead program, SB-007 — the first dual AAV gene therapy in clinical development for #StargardtDisease.
📅 31 May
🕛 12:00–1:30 PM BST
Register here: bit.ly/4dF9viD
5
155
May is #HealthyVisionMonth 👁️We are proud to support the #Stargardtdisease community – this March, we dosed the first patient in our Phase 1/2 ASTRA study! Learn more about our mission to address inherited #retinal diseases: bit.ly/42u9U3Z
3
130
Heading to #ASGCT2025? Connect with #SpliceBio in New Orleans!
Meet CEO Miquel Vila Perello & CBO Gerard Caelles and learn about SB-007 — the first dual AAV #genetherapy in the clinic for #StargardtDisease. The first patient was dosed in the Phase 1/2 ASTRA study in March 2025.
1
4
402
Meet us in Salt Lake City at #ARVO2025!
The #SpliceBio team will be at @ARVOinfo's premier conference for eye & vision specialists from May 4-8. 📅
Learn about our dual AAV gene therapy for #Stargardtdisease, SB-007, and the Phase 1/2 ASTRA study! 🚀
2
142
The #SpliceBio team is heading to Salt Lake City for the Retinal Therapeutics Innovation Summit 2025 on 2 May! Excited to share updates on our dual AAV #genetherapy, SB-007, and connect with leaders in #biotech, #ophthalmology & research.
#Stargardtdisease.
1
7
213
Heading to #CGMed25 from📅15–17 April? #SpliceBio will be in Rome for Europe’s premier cell & gene therapy conference!
Let’s connect and discuss our dual AAV #genetherapy, SB-007, for the treatment of Stargardt disease, currently in Phase 1/2 development in the ASTRA study🚀.
2
139
This #WorldOptometryDay, 23rd March. We at #SpliceBio are proud to be working alongside the #Stargardtdisease patient community to bring a potential treatment option to patients with our dual-AAV gene therapy, SB-007. SB-007 is advancing in the clinic in a Phase 1/2 ASTRA study.
5
126
#SpliceBio's CBO, Gerard Caelles to participate in a panel discussion at the @FightBlindness Investing in Cures Summit in Tampa, Florida on 22 March!
Listen in from 14:40-15:20 EDT to learn more about the advancements of genetic medicine strategies to address retinal diseases.
2
78